Co-occurring Melanoma in an Active Area of Vitiligo in Skin of Color
The association between vitiligo and melanoma is complex. While the incidence of vitiligo in patients with melanoma is higher, the risk for the reverse, ie, the development of melanoma in a patient with vitiligo, is thought to be decreased. This report presents a case of melanoma developing on a non-sun-exposed site in a patient with skin of color and untreated vitiligo. It emphasizes the need …
The association between vitiligo and melanoma is complex. While the incidence of vitiligo in patients with melanoma is higher, the risk for the reverse, ie, the development of melanoma in a patient with vitiligo, is thought to be decreased. This report presents a case of melanoma developing on a non-sun-exposed site in a patient with skin of color and untreated vitiligo. It emphasizes the need … Continue reading "Co-occurring Melanoma in an Active Area of Vitiligo in Skin of Color"
JDD authors Deepika Narayanan, MD and Stephen K. Tyring, MD, PhD, MBA present a case of a patient with a 10-year history of blue-black macules and patches on the face and an associated history of skin- lightening cream usage. The skin lightening cream contained hydroquinone, which is often associated with exogenous ochronosis (EO). Interestingly, the biopsy did not show characteristic findings of … 
INTRODUCTION
Melanoma accounts for only 1% of all skin cancers but is responsible for most skin cancer-related deaths.1 Acral and mucosal melanoma (AMM) accounts for only 4% of all new melanomas but is associated with poorer prognosis.2 Patients of color are disproportionately affected by AMM. Elucidating the clinical, genetic, and environmental features of AMM can guide advancements in the … 
Syringomas are benign neoplasms derived from eccrine sweat glands. Eruptive syringomas are a subtype of syringomas and are typically located on the chest, neck, and abdomen during puberty or childhood. Herein, JDD authors Jennifer Wang BA, Nyousha Yousefi MD, Edward Heilman MD FAAD FCAP, and Jared Jagdeo MD MS present a 20-year-old African American female with an atypical case of eruptive syringom … 
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to … 